Jakse G, Hofstädter F, Marberger H
J Urol. 1981 Feb;125(2):185-90. doi: 10.1016/s0022-5347(17)54959-9.
We treated 15 patients with carcinoma in situ of the bladder by intravesical instillation of doxorubicin hydrochloride. Different dose and interval schedules, that is 40 mg. biweekly and 80 mg. monthly, each resulted in a 66 per cent tumor remission rate. In no instance were undue systemic effects noted; the local side effects were negligible. Cold cup random biopsies were obtained before and during therapy. Light and electron microscopic evaluation revealed a gradual redifferentiation of the malignant urothelium in the course of treatment. In addition, A, B and H antigenicity was assessed and showed a recurrence of initially lacking surface isoantigens in patients with tumor remission.
我们采用膀胱内灌注盐酸阿霉素的方法治疗了15例膀胱原位癌患者。不同的剂量和给药间隔方案，即每两周40毫克和每月80毫克，每种方案的肿瘤缓解率均为66%。未观察到任何明显的全身影响；局部副作用可忽略不计。在治疗前和治疗期间进行了冷杯随机活检。光镜和电镜评估显示，在治疗过程中恶性尿路上皮逐渐重新分化。此外，对A、B和H抗原性进行了评估，结果显示肿瘤缓解患者最初缺乏的表面同种抗原出现了复发。
